Orion Corporation Set to Announce Financial Results for 2024
Orion Corporation has exciting plans as it prepares to release its Financial Statement for the year 2024 on February 25, 2025, at approximately 12:00 noon EET. This release will include comprehensive insights into the company's performance, expectations, and future outlook. As a testimony to its commitment to transparency, the release along with supporting presentation materials will be accessible on their official website soon after publication.
Join the Live Webcast and Conference Call
Upon the announcement of the financial results, Orion will host a live webcast and conference call aimed at analysts, investors, and the media, scheduled for February 25, 2025, at 1:30 PM EET. This interactive session will provide a platform for detailed discussions on the findings of the financial report and future projections of Orion Corporation.
Accessing the Webcast
The link to the live webcast will be available on Orion's Investor Relations website, ensuring that all interested parties can participate in real-time discussions. A recording of the webcast will also be available for viewing on the same day, allowing those who are unable to attend live to catch up on critical information presented.
Participation Details for Analysts and Investors
For those wishing to participate in the conference call, registration will be required. Once registered, participants will receive the necessary phone numbers and conference ID to join the conversation. It is encouraged for attendees to prepare any questions in advance, as there will be an opportunity to engage during the call by entering the question queue.
Orion Corporation: A Leader in Pharmaceuticals
Orion Corporation is recognized as a leading Finnish pharmaceutical company, dedicated to improving health outcomes globally. With a variety of pharmaceutical products at their disposal, ranging from human health medications to veterinary pharmaceuticals, Orion actively contributes to the well-being of individuals and communities. Their robust portfolio encompasses both proprietary and generic medicines, showcasing a strong commitment to comprehensive healthcare.
Focus Areas in Pharmaceutical Development
The company's pharmaceutical research and development efforts are concentrated in critical areas such as oncology and pain management. Many proprietary products developed by Orion address significant health challenges, including cancer and neurological disorders, enabling better management and treatment for these conditions. As a testament to their success, Orion reported net sales of EUR 1,341 million in the previous fiscal year, showcasing their sustained growth and impact within the market.
Contact Information for Inquiries
For further inquiries related to the Financial Statement Release or to engage with investor relations, individuals can reach out to Tuukka Hirvonen, who manages the Investor Relations at Orion Corporation. He is readily available to address any questions or provide additional information as needed.
Frequently Asked Questions
What is the date of Orion Corporation's Financial Statement Release?
The Financial Statement Release for Orion Corporation is scheduled for February 25, 2025.
How can I access the webcast for the Financial Statement?
You can access the webcast on Orion's Investor Relations website shortly after the financial results are announced.
Who can participate in the conference call?
The conference call is open to analysts, investors, and media representatives, requiring registration to participate.
What are the main therapy areas that Orion focuses on?
Orion Corporation focuses primarily on oncology and pain management within its pharmaceutical research and development sectors.
How can I contact Orion Corporation for more information?
For inquiries, you can reach out to Tuukka Hirvonen in the Investor Relations department at +358 10 426 2721.
